Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Carcinoma, Renal Cell 1Adenocarcinoma, Follicular 1

Interventions

Trastuzumab 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1sargramostim 1aldesleukin 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Interviews as Topic 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × Rosiglitazone × Genitourinary × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡